Evidence map›Paper›PMID 32601850›Full record

Trial reportJournal of thrombosis and thrombolysis2020

Detailed thrombogenicity phenotyping and 1 year outcomes in patients undergoing WATCHMAN implantation: (TARGET-WATCHMAN) a case-control study.

Matthew Sherwood, Kevin P Bliden, Leonard Ilkhanoff, Ganesh Venkataraman, Adam Strickberger, Sharam Yazdani, Robert McSwain, Haroon Rashid, Eliano P Navarese, Tracy Plummer and 4 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Journal of thrombosis and thrombolysis, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.5field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. SCAI/HRS Expert Consensus Statement on Transcatheter Left Atrial Appendage Closure.Journal of the Society for Cardiovascular Angiography & Interventions
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Matthew SherwoodInova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute, Fairfax, VA, USA.
Kevin P BlidenSinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, Baltimore, MD, USA.
Leonard IlkhanoffInova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute, Fairfax, VA, USA.
Ganesh VenkataramanColorado Heart & Vascular, Lakewood, CO, USA.
Adam StrickbergerInova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute, Fairfax, VA, USA.
Sharam YazdaniInova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute, Fairfax, VA, USA.
Robert McSwainInova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute, Fairfax, VA, USA.
Haroon RashidInova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute, Fairfax, VA, USA.
Eliano P NavareseCardiovascular Institute, Mater Dei Hospital, Bari BA, Italy.
Tracy PlummerInova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute, Fairfax, VA, USA.
Wayne BatchelorInova Center for Thrombosis Research and Drug Development, Inova Heart and Vascular Institute, Fairfax, VA, USA.
Rahul ChaudharySinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, Baltimore, MD, USA.
Udaya S TantrySinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, Baltimore, MD, USA.
Paul A GurbelSinai Center for Thrombosis Research and Drug Development, Sinai Hospital of Baltimore, Baltimore, MD, USA. Pgurbel@lifebridgehealth.org.ORCID http://orcid.org/0000-0002-5461-568X
Sinai Hospital · USMayo Clinic · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The relation of device related thrombosis (DRT) and major bleeding after left atrial appendage closure (LAAC) to laboratory thrombosis and hemostasis markers has not been studied. We performed a prospective case control study to identify clinical characteristics and laboratory markers in patients who developed DRT and major bleeding following WATCHMAN LAAC. Thromboelastography, platelet aggregation (PA), urinary 11-dehydrothromboxane B

Indexed as

AgedAged, 80 and overAnticoagulantsAtrial AppendageAtrial FibrillationBlood CoagulationCase-Control StudiesFemaleHeart-Assist DevicesHemorrhageHemostasisHumansMaleProspective StudiesThrombosisTreatment OutcomeAnticoagulantsAntithrombotic therapyPlatelet aggregationTEGThrombotic riskWatchman

Identifiers

PMID32601850
OpenAlexW3037599928

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.